CN102105133B - 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法 - Google Patents

控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法 Download PDF

Info

Publication number
CN102105133B
CN102105133B CN200980128665.8A CN200980128665A CN102105133B CN 102105133 B CN102105133 B CN 102105133B CN 200980128665 A CN200980128665 A CN 200980128665A CN 102105133 B CN102105133 B CN 102105133B
Authority
CN
China
Prior art keywords
otic
ear
instances
otic structure
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980128665.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102105133A (zh
Inventor
杰伊·利希特尔
贝内迪克特·福尔拉特
安德鲁·M·特拉梅尔
塞尔希奥·G·杜龙
法布里斯·皮乌
路易斯·A·德拉玛丽
叶强
卡尔·勒贝尔
迈克尔·克里斯托弗·斯凯夫
杰弗里·P·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otonomy Inc
University of California, San Diego
Original Assignee
Otonomy Inc
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otonomy Inc, University of California, San Diego filed Critical Otonomy Inc
Priority to CN201510260647.2A priority Critical patent/CN104940126A/zh
Publication of CN102105133A publication Critical patent/CN102105133A/zh
Application granted granted Critical
Publication of CN102105133B publication Critical patent/CN102105133B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980128665.8A 2008-07-21 2009-07-20 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法 Expired - Fee Related CN102105133B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510260647.2A CN104940126A (zh) 2008-07-21 2009-07-20 控制释放型耳结构调节和先天性免疫系统调节组合物、装置以及治疗耳部病症的方法

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US8245008P 2008-07-21 2008-07-21
US61/082,450 2008-07-21
US9120008P 2008-08-22 2008-08-22
US9120508P 2008-08-22 2008-08-22
US61/091,200 2008-08-22
US61/091,205 2008-08-22
US9438408P 2008-09-04 2008-09-04
US61/094,384 2008-09-04
US10111208P 2008-09-29 2008-09-29
US61/101,112 2008-09-29
US10884508P 2008-10-27 2008-10-27
US61/108,845 2008-10-27
US14003308P 2008-12-22 2008-12-22
US61/140,033 2008-12-22
US15677109P 2009-03-02 2009-03-02
US61/156,771 2009-03-02
PCT/US2009/051165 WO2010011605A2 (en) 2008-07-21 2009-07-20 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510260647.2A Division CN104940126A (zh) 2008-07-21 2009-07-20 控制释放型耳结构调节和先天性免疫系统调节组合物、装置以及治疗耳部病症的方法

Publications (2)

Publication Number Publication Date
CN102105133A CN102105133A (zh) 2011-06-22
CN102105133B true CN102105133B (zh) 2015-06-17

Family

ID=41568836

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980128665.8A Expired - Fee Related CN102105133B (zh) 2008-07-21 2009-07-20 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法

Country Status (8)

Country Link
US (1) US10092580B2 (enExample)
EP (1) EP2306975A4 (enExample)
JP (1) JP5421366B2 (enExample)
CN (1) CN102105133B (enExample)
AU (1) AU2009274229B2 (enExample)
CA (1) CA2731769C (enExample)
HK (1) HK1215394A1 (enExample)
WO (1) WO2010011605A2 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
CA2751761A1 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
US20140076336A1 (en) * 2009-09-17 2014-03-20 Ascentia Health, Inc. Ear insert for relief of tmj discomfort and headaches
EP2545075B1 (en) * 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
BR112012026542A2 (pt) 2010-04-16 2016-07-12 Momenta Pharmaceuticals Inc abordagem seletiva de tecido
AU2011268470B2 (en) 2010-06-17 2017-02-02 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
US9943522B2 (en) * 2011-05-16 2018-04-17 Bayer Intellectual Property Gmbh Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US10220002B2 (en) * 2011-12-02 2019-03-05 Board Of Regents Of The University Of Nebraska Controlled-release peptide compositions and uses thereof
EP4772625A2 (en) 2012-01-12 2026-07-08 Endo Biologics Limited Clostridium histolyticum enzyme
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
EP2854553B1 (de) * 2012-03-30 2016-12-21 SapioTec GmbH Verwendung von delphinidin gegen staphylococcus aureus
WO2013188534A1 (en) * 2012-06-12 2013-12-19 Rutgers, The State University Of New Jersey Biomaterials for the prevention of post-operative adhesions
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
TWI485145B (zh) 2012-10-26 2015-05-21 財團法人工業技術研究院 Ｐ型有機半導體材料與光電元件
CN109260465A (zh) * 2012-11-14 2019-01-25 史密夫和内修公司 稳定的嗜热菌蛋白酶水凝胶
WO2014105635A1 (en) * 2012-12-27 2014-07-03 Sentiss Pharma Pvt.Ltd. Sterile ophthalmic pharmaceutical suspensions
US20160000890A1 (en) * 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
WO2014144859A1 (en) 2013-03-15 2014-09-18 Biospecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
CN105050629B (zh) 2013-03-15 2018-09-25 史密夫和内修公司 用于递送活性剂的可溶解的形成凝胶的膜
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
CN105682742A (zh) 2013-08-27 2016-06-15 奥德纳米有限公司 小儿耳部病症的治疗
CN103751102A (zh) * 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US10183064B2 (en) 2014-03-20 2019-01-22 Technion Research & Development Foundation Limited Delivery system comprising a proteolytic enzyme or effector thereof for use in a method for oral treatment and uses thereof
WO2015161175A1 (en) * 2014-04-17 2015-10-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of chemical cochleostomy
US20150374779A1 (en) * 2014-06-26 2015-12-31 Auris Medical Ag Pharmacologic treatments of meniére's disease
KR20170052574A (ko) * 2014-07-29 2017-05-12 오토노미, 인코포레이티드 이구분해의 치료를 위한 귀 제제
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
BR112017019241A2 (pt) * 2015-03-11 2018-05-08 Univ Nebraska análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico
WO2016154432A1 (en) * 2015-03-24 2016-09-29 VaxLiant, LLC Adjuvant compositions and related methods
CA2896038C (en) 2015-07-03 2022-08-09 Glycobiosciences Inc. Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof
WO2017038473A1 (ja) * 2015-08-28 2017-03-09 天野エンザイム株式会社 エンドトキシン低減サーモリシン
CN105168618A (zh) * 2015-10-07 2015-12-23 郑文忠 一种用于治疗大疱性鼓膜炎的中药
US12029829B2 (en) 2016-03-22 2024-07-09 President And Fellows Of Harvard College Biocompatible adhesives and methods of use thereof
ES3042094T3 (en) * 2016-05-20 2025-11-18 Azure Biotech Inc Vaginal delivery systems containing selective estrogen receptor modulator (serm) and uses thereof
AU2017290082A1 (en) * 2016-06-30 2018-12-13 Next Science IP Holdings Pty Ltd Antimicrobial compositions and methods employing same
DK3589204T3 (da) 2017-03-01 2025-06-30 Endo Operations Ltd Apparat og fremgangsmåde til vurdering og behandling af cellulitis
KR20250171475A (ko) 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법
CN109134869B (zh) * 2018-07-04 2020-10-20 吉林大学 过氧化氢响应型靶向荧光载药纳米材料及制备方法
EP3894864A2 (en) * 2018-12-10 2021-10-20 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
WO2020198431A1 (en) * 2019-03-26 2020-10-01 University Of Cincinnati Method of making prodrug for sustained and controlled release
EP4031131A4 (en) * 2019-09-20 2024-01-03 President and Fellows of Harvard College STRONG GEL DRUG DELIVERY COMPOSITIONS AND ASSOCIATED METHODS
AU2020366008B2 (en) 2019-10-15 2025-08-28 Biospecifics Technologies Corp. Treatment of uterine fibroids using purified collagenase
US12246024B2 (en) 2019-12-13 2025-03-11 Free State Pharma Inc Compositions and methods for controlling cerumen production
WO2021252719A1 (en) * 2020-06-11 2021-12-16 The Trustees Of Columbia University In The City Of New York Methods and compositions for preventing and treating myopia with s-methyl-l-thiocitrulline, a selective neuronal nitric oxide synthase (nnos) inhibitor, and derivatives thereof
US11672773B2 (en) 2020-12-13 2023-06-13 Next Science IP Holdings Pty Ltd Methods for treating ciliated cavities
US20250108037A1 (en) 2021-11-08 2025-04-03 Mitsubishi Gas Chemical Company, Inc. Composition containing ergothioneine for suppressing or preventing inner ear hearing loss
WO2023086806A1 (en) * 2021-11-09 2023-05-19 The University Of Chicago Compositions and methods for inducing immune tolerance
CN116433679B (zh) * 2023-04-07 2026-01-30 北京工业大学 一种基于空间位置结构先验的内耳迷路多级标注伪标签生成与分割方法
CN116920155A (zh) * 2023-07-20 2023-10-24 江苏中科生命科学研究有限公司 一种生物相容性好抗排异的生物护创膜
CN117442601B (zh) * 2023-10-31 2024-05-28 上海市东方医院（同济大学附属东方医院） 一种磷酸酶抑制剂类似物BX-金属NPs及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316011B1 (en) * 1998-08-04 2001-11-13 Madash, Llc End modified thermal responsive hydrogels
US20040101560A1 (en) * 2002-11-27 2004-05-27 Sawchuk Ronald J. Methods and compositions for applying pharmacologic agents to the ear

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4474572A (en) 1981-09-29 1984-10-02 Syntex (U.S.A.) Inc. Implanting device and implant magazine
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4758435A (en) 1986-08-11 1988-07-19 American Cyanamid Company Estradiol implant composition and method for preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
AU6952391A (en) 1989-11-29 1991-06-26 Brigham And Women's Hospital (ala il-8)77 as a leukocyte adhesion inhibitor
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
IT1251151B (it) * 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
EP0551626A1 (en) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ES2113094T3 (es) 1993-03-09 1998-04-16 Epic Therapeutics Inc Las microparticulas macromoleculares y metodos de obtencion.
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5714344A (en) 1993-04-07 1998-02-03 Georgetown University Protease-derivatized CVF
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
CN1106259A (zh) * 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US6110892A (en) 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
GB9505032D0 (en) 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
AU2676397A (en) 1996-04-18 1997-11-07 University Technology Corporation Methods for treating middle and inner ear disorders
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
DE69833000T2 (de) 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
DE19748763A1 (de) 1997-11-05 1999-05-06 Hans Peter Zenner Verwendung von Vasopressin-Antagonisten
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
SE9901272D0 (sv) 1999-04-09 1999-04-09 Astra Ab New improved formulation
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6537540B1 (en) 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US20060269602A1 (en) * 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
TWI324925B (en) 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
US7132110B2 (en) * 2001-08-30 2006-11-07 Isotis Orthobiologics, Inc. Tissue repair compositions and methods for their manufacture and use
JP4623962B2 (ja) 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
MXPA04005427A (es) 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
RS63204A (sr) 2002-01-17 2006-10-27 Neurogen Corporation Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
JP2005531574A (ja) 2002-05-22 2005-10-20 アムジエン・インコーポレーテツド 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体
TW200410945A (en) 2002-08-08 2004-07-01 Amgen Inc Vanilloid receptor ligands and their use in treatments"
US20060013858A1 (en) * 2002-10-29 2006-01-19 Trune Dennis R Fludrocortisone treatment for hearing loss
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
US7279499B2 (en) 2003-04-21 2007-10-09 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
EP1648878B9 (en) 2003-07-24 2011-03-16 Euro-Celtique S.A. Piperidine compounds and pharmaceutical compositions containing them
US7390907B2 (en) 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7700086B2 (en) * 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
WO2005115527A2 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US8498681B2 (en) 2004-10-05 2013-07-30 Tomophase Corporation Cross-sectional mapping of spectral absorbance features
US20060105967A1 (en) 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Flavone derivatives as TNFalpha inhibitors or antagonists
CA2593482A1 (en) 2005-01-14 2006-07-20 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
JP2008537684A (ja) * 2005-01-24 2008-09-25 ニューロシステック コーポレイション 内耳およびその他の組織へ治療薬および／またはその他の薬剤を送達するための装置および方法
AU2006208042A1 (en) 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
US20060221197A1 (en) 2005-03-30 2006-10-05 Jung Edward K Image transformation estimator of an imaging device
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EP2932971A1 (en) * 2005-03-04 2015-10-21 Otonomy, Inc. Ketamine formulations
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
EP1858865B1 (en) 2005-03-10 2009-09-16 Pfizer Inc. Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds
US7312233B2 (en) 2005-03-14 2007-12-25 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EA200701745A1 (ru) 2005-03-17 2008-06-30 Пфайзер, Инк. Циклопропанкарбоксамидные производные
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
ES2382876T3 (es) 2005-05-31 2012-06-14 Pfizer, Inc. Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP1928439A4 (en) 2005-09-26 2009-04-29 Piedmont Pharmaceuticals Llc METHOD FOR THE TREATMENT AND PREVENTION OF OTITIS MEDIA WITH CHEMICAL PENETRATION AMPLIFIERS TO FACILITATE THE TRANSMEMBRANOESE DRUG DELIVERY IN THE MIDDLE EAR
CN101272807A (zh) 2005-09-26 2008-09-24 皮埃蒙特医药品有限公司 使用非离子表面活性剂促进跨膜药物输送到中耳治疗和预防中耳炎的方法
CA2620374C (en) * 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US20070110788A1 (en) 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US20080031847A1 (en) * 2005-12-22 2008-02-07 Pluromed, Inc. Methods and kits for treating lacerations and puncture wounds using inverse thermosensitive polymers
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
WO2008027880A2 (en) 2006-08-28 2008-03-06 Brookler Kenneth H Strontium-based treatment of otosclerosis
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2008049196A1 (en) * 2006-10-27 2008-05-02 Iomedix Development International Srl Composition for improving blood cholesterol levels
US20100179092A1 (en) 2006-11-15 2010-07-15 Fritzinger David C Human complement c3 derivatives with cobra venom factor-like function
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
MY161021A (en) * 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316011B1 (en) * 1998-08-04 2001-11-13 Madash, Llc End modified thermal responsive hydrogels
US20040101560A1 (en) * 2002-11-27 2004-05-27 Sawchuk Ronald J. Methods and compositions for applying pharmacologic agents to the ear

Also Published As

Publication number Publication date
AU2009274229B2 (en) 2013-08-22
CA2731769A1 (en) 2010-01-28
WO2010011605A2 (en) 2010-01-28
EP2306975A4 (en) 2012-10-31
US20100021416A1 (en) 2010-01-28
JP5421366B2 (ja) 2014-02-19
JP2011528716A (ja) 2011-11-24
AU2009274229A1 (en) 2010-01-28
CA2731769C (en) 2013-09-10
EP2306975A2 (en) 2011-04-13
US10092580B2 (en) 2018-10-09
WO2010011605A3 (en) 2010-05-14
CN102105133A (zh) 2011-06-22
HK1215394A1 (zh) 2016-08-26

Similar Documents

Publication Publication Date Title
US10092580B2 (en) Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US10918594B2 (en) Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
AU2009271129B2 (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US8496957B2 (en) Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CA2731766C (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
JP6207093B2 (ja) 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
CN104940126A (zh) 控制释放型耳结构调节和先天性免疫系统调节组合物、装置以及治疗耳部病症的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150617

Termination date: 20180720